戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tive than alendronate, which acts only as an antiresorptive.
2 ng a window for prophylaxis with long-acting antiresorptives.
3  in rats can be ameliorated by bone-targeted antiresorptives.
4 at intervals of 2 weeks, displays a powerful antiresorptive action in vivo.
5                                 Although the antiresorptive action of estrogen arises from the inhibi
6                                 However, the antiresorptive action of estrogen decreased the extent o
7                    This profound and lasting antiresorptive action of TSH is mimicked in cells that g
8 n mice through a combination of anabolic and antiresorptive actions on the skeleton.
9 bitors on bone formation together with their antiresorptive actions specify the osteoprotective actio
10  Representative inhibitors have demonstrated antiresorptive activity both in vitro and in vivo and th
11 e adsorption assay, and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced
12                  This study investigates the antiresorptive activity of tanshinone as an adjuvant the
13                                         This antiresorptive activity was abolished by phenylmethylsul
14 dronate (IG9402, a bisphosphonate that lacks antiresorptive activity) at 10(-9) to 10(-6) M prevented
15 r (AP22408) of Src that demonstrates in vivo antiresorptive activity.
16  impact of a locally or systemically applied antiresorptive agent (alendronate) on simvastatin-induce
17 thyroid hormone in the future, the choice of antiresorptive agent should be carefully considered.
18                      Alendronate (ALN) is an antiresorptive agent widely used for the treatment of os
19 e that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone min
20  is also possible that the combination of an antiresorptive agent with an anabolic agent could be mor
21 reatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build o
22 y, whose appearance could be prevented by an antiresorptive agent.
23 a T score of <=-2.5 for BMD), followed by an antiresorptive agent.
24 in the presence of zoledronic acid, a potent antiresorptive agent.
25 if parathyroid hormone is not followed by an antiresorptive agent.
26  10-year absolute fracture risk (eg, >=20%), antiresorptive agents (bisphosphonates or, if contraindi
27 ologists were less likely to be treated with antiresorptive agents (OR 0.49 [95% CI 0.28-0.86]).
28 nstay of treatment for osteoporosis has been antiresorptive agents (such as bisphosphonates), which h
29  use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed.
30                                        Novel antiresorptive agents are being developed.
31                                          The antiresorptive agents are clearly able to preserve bone
32                                              Antiresorptive agents are widely used to treat osteoporo
33 ation, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive ou
34                      Therapy with individual antiresorptive agents has been shown to be effective for
35    To reduce bone loss and improve strength, antiresorptive agents have been instituted.
36 e effects of these pharmacologically diverse antiresorptive agents on gene expression in bone has not
37                                              Antiresorptive agents such as bisphosphonates are used w
38                                              Antiresorptive agents such as bisphosphonates or denosum
39 ciated bone disease are available, including antiresorptive agents such as denosumab and bisphosphona
40  be used either alone or in combination with antiresorptive agents to build new bone and reduce fract
41 rapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes.
42 fonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in d
43                                              Antiresorptive agents, especially bisphosphonates, appea
44 se findings suggest that, among women taking antiresorptive agents, greater increases in BMD are asso
45  coincident with a decline in the use of the antiresorptive agents.
46 effect in patients undergoing treatment with antiresorptive agents.
47 pounds for the development of a new class of antiresorptive agents.
48 rug therapy for osteoporosis including novel antiresorptive and anabolic agents that may become avail
49 n unmet need to develop new agents with both antiresorptive and anabolic effects to treat osteoporosi
50 h to management and concerns associated with antiresorptive and anabolic therapies.
51 s suggests that these compounds possess dual antiresorptive and anti-inflammatory properties, making
52 otentially serious condition associated with antiresorptive and antiangiogenic therapies.
53                 Bis-enoxacin, which has both antiresorptive and antibiotic activities, was more effec
54 mulation of this metabolite accounts for the antiresorptive and antimacrophage effects of clodronate.
55 ontinuation is dependent on both the type of antiresorptive and the timing of discontinuation.
56 moving beyond traditional monotherapies with antiresorptives and anabolic agents into new combination
57              Surprisingly, the bone-targeted antiresorptives bis-enoxacin and alendronate inhibited i
58            The exact mechanisms of action of antiresorptive bisphosphonate drugs remain unclear, alth
59 e, when these Wnt agonists are combined with antiresorptive bisphosphonates or anti-sclerostin antibo
60  a new pyridinyl bisphosphonate, is a potent antiresorptive bone agent.
61                                              Antiresorptives can be discontinued prior to oral surgic
62        Botanicals and their relation to bone antiresorptive capacity, cognitive function, vascular ef
63  helper cells that can function as a pro- or antiresorptive cytokine, but the reason why IFN-gamma ha
64 s with additional drugs, especially the bone antiresorptive denosumab.
65     In conclusion, our findings suggest that antiresorptive discontinuation is dependent on both the
66                                              Antiresorptive discontinuation, often termed a "drug hol
67 , calcium and vitamin D supplementation, and antiresorptive drug treatment.
68                  Zoledronic acid (ZOL) is an antiresorptive drug used to prevent bone loss in a varie
69 onths, treatment should be continued with an antiresorptive drug.
70 gnificant association between overall use of antiresorptive drugs and the presence of knee pain and r
71                               Bisphosphonate antiresorptive drugs are the approved treatment for soli
72 ures are needed to determine whether and how antiresorptive drugs can be optimally used in conjunctio
73                                        While antiresorptive drugs have been the cornerstone of osteop
74 arily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption.
75                                              Antiresorptive drugs were prescribed in 26%, 12%, 7%, an
76 art of the maxilla as a consequence of these antiresorptive drugs.
77  patients receiving long-term treatment with antiresorptive drugs.
78 mong these women, 214 (26.2%) were receiving antiresorptive drugs.
79       Overall these studies suggest that the antiresorptive effects of anti-TNF therapy are related t
80 group (p = 0.002), consistent with the known antiresorptive effects of bisphosphonates.
81 irect evidence that the antiinflammatory and antiresorptive effects of clodronate on macrophages and
82            These data demonstrate the potent antiresorptive effects of muRANK.Fc in vivo as well as h
83                                          The antiresorptive effects of TNF inhibitors are likely rela
84 e critical cytokine mediating the downstream antiresorptive effects of TSH on the skeleton.
85 tiangiogenic effects of cabozantinib and the antiresorptive effects of zoledronic acid.
86 cing kinase inhibitor with dual anabolic and antiresorptive effects on bone and could represent a new
87  R = 0.74, p < 0.0001) are closely linked to antiresorptive efficacy.
88                                Several novel antiresorptive mechanisms are currently under considerat
89 ctor kappaB ligand (RANKL), is a widely used antiresorptive medication for osteoporosis treatment.
90  with 1995-1998, and the use of prescription antiresorptive medication increased approximately 2-fold
91 or measurement of bone mass, prescription of antiresorptive medication, and use of over-the-counter c
92 s of the jaws (ONJ), a severe side effect of antiresorptive medications, is characterized by exposed,
93 s (ONJ) is a rare but severe complication of antiresorptive medications, such as bisphosphonates, use
94 ss a conceptual framework of agents that are antiresorptive or anabolic, and review pathways that aff
95 ess fracture risk, and reduce that risk with antiresorptive or other available therapies.
96                 Animals were pretreated with antiresorptives or saline, after which we induced ONJ us
97               The CoMFA predicted (rat) bone antiresorptive pLED values are in agreement with literat
98 eutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting fur
99 the effectiveness of a regimen combining the antiresorptive properties of nasal calcitonin with the o
100                          In keeping with its antiresorptive properties, ritonavir impairs receptor ac
101 surgical periodontal therapy offering strong antiresorptive properties.
102  TIL may influence its anti-inflammatory and antiresorptive properties.
103   Transplant recipients were treated with an antiresorptive regimen that included a bisphosphonate st
104 ated, and no causal association between bone antiresorptive regimens and MRONJ has yet been establish
105 n negative regulator of the proformative and antiresorptive role of the Wnt signaling pathway in the
106                           Development of new antiresorptive therapies calls for a holistic understand
107  distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporos
108 bitors of transforming growth factor-beta or antiresorptive therapies may be effective enhancers of a
109                                      Current antiresorptive therapies provide limited benefit, and no
110 seful to assess the response to anabolic and antiresorptive therapies, to assess compliance to therap
111 orosis has traditionally involved the use of antiresorptive therapies.
112 y result in the development of improved bone antiresorptive therapies.
113 to quantify bone turnover in women receiving antiresorptive therapy compared with that of untreated c
114  would provide a strong rationale for use of antiresorptive therapy for the prevention and treatment
115 continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in
116                                        While antiresorptive therapy is the mainstay of OI treatment,
117                           This suggests that antiresorptive therapy may be discontinued at the end of
118                            Patients received antiresorptive therapy once per month without de-escalat
119 o two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone
120  breast cancer and bone metastases receiving antiresorptive therapy were finally included in the stud
121                                              Antiresorptive therapy with a bisphosphonate decreases t
122 pausal osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates
123 planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, t
124 ) is one of the most important toxicities of antiresorptive therapy, which is standard practice for p
125 astogenesis and is a potential candidate for antiresorptive therapy.
126 agents might have greater potential than the antiresorptives to increase bone mass and to decrease fr
127  protection compared with either anabolic or antiresorptive treatment alone.
128 tomy and additionally changed by one or more antiresorptive treatment.
129 TCG) finds convincing evidence that adjuvant antiresorptive treatments provide persistent benefits to
130                                              Antiresorptive treatments such as bisphosphonates preven
131 cted by baseline risk indicators, except for antiresorptive treatments that showed a greater reductio
132 nd systemic inflammation, and the success of antiresorptive treatments will rely on how effectively t
133            In our first experimental design, antiresorptives were discontinued 1 wk prior to tooth ex
134 e second experiment, ONJ was established and antiresorptives were discontinued for 4 wk.
135             We previously showed long-acting antiresorptive zoledronic acid (ZOL) prevented ART-induc

 
Page Top